Novoron Bioscience, Inc. was founded in 2013 to advance pioneering research on spinal cord nerve regeneration. The company’s mission, however, has evolved to fully exploit the potential of its intellectual discoveries to develop novel therapeutic approaches for the treatment of multiple disorders of the central nervous system (CNS): multiple sclerosis (MS), spinal cord injury, glaucoma and stroke. To date, we have secured more than $1.2 million in NIH grants under the SBIR/STTR program.
Our founders and scientific advisors are dedicated to understanding nerve regeneration to find new treatments for CNS disorders and diseases.
Dr. Travis Stiles, CEO & President
For nearly a decade, Dr. Travis Stiles has exclusively studied the mechanisms underlying regenerative failure in the central nervous system (CNS). His work led to the discovery of a novel therapeutic target for the promotion of neuronal tissue regeneration after CNS damage and/or disease. His work has demonstrated this novel target is a central regulator of the convergence of a diverse array of molecular factors that cause catastrophic failure of neuronal regeneration in the CNS, thereby making it an exciting intervention point for restoring the regenerative capacity of the brain and spinal cord. To best translate his work into clinically viable therapies, Dr. Stiles co-founded Novoron Bioscience, Inc. early in 2013. Since that time Novoron has raised approximately $1.5 MM in NIH grant funding and now holds exclusive licenses from the University of California, San Diego (UCSD) to two intellectual property assets of which Dr. Stiles was the primary inventor. Travis earned a Ph.D. in Biomedical Science from UCSD, a M.A. in Exercise Physiology from the University of the Pacific, and a B.A. in Exercise Science from Willamette University.
Dr. James E. Callaway, Chief Operation Officer
Dr. Callaway is an experienced biotech executive (former CEO of ArmaGen and CEBIX) who has led efforts in transitioning research companies to clinical stage operating entities. His experience with biologic therapeutics is highlighted by his work on Tysabri, which was one of the first biologics for CNS disease and is still widely used for treatment of multiple sclerosis. His experience as both a researcher and corporate executive make him an invaluable addition to the Novoron team. Jim earned a Ph.D. in Biological Chemistry from the University of California, Los Angeles and a B.S. in Chemistry from California State University, Chico.
Dr. A. Taylor Bright, Corporate Development Officer
Dr. Taylor Bright’s passion lies in the translation of exciting academic science into clinically viable commercial applications. As a co-founder of Novoron Bioscience, Dr. Bright has applied this passion into leveraging his academic and industry experience to advance Dr. Stiles’ discoveries out of UCSD and into Novoron Bioscience’s technology pipeline. His extensive research experience in cell biology, cell culture, and molecular biology is well-served by his competency in bioinformatics and computational biology. In addition, he has experience in protocol design and optimization as well as project management. Taylor earned a Ph.D. in Biomedical Science from UCSD and an A.B. from Princeton University.
Shawn Gahr, Corporate Development Officer
Shawn Gahr is a co-founder of Novoron Bioscience. Mr. Gahr has nearly a decade of experience in financial analysis, business development, and project
management with high-profile start-up companies, such as Apptio and Imperium Renewables. Shawn earned an M.P.I.A. in International Economics from UCSD, a B.S. in Business-Economics from Willamette University and holds a Certificate in Biomedical Regulatory Affairs from the University of Washington.
Scientific Advisory Board
Dr. James E. Callaway, Scientific Advisor
James Callaway, Ph.D. is an experienced biotech executive who has led efforts in transitioning research companies to clinical stage operating entities. His experience with biologic therapeutics is highlighted by his work on Tysabri, which was one of the first biologics for CNS disease and is still widely used for treatment of multiple sclerosis. His experience as both a researcher and corporate executive make him an invaluable addition to the Novoron team. Dr. Callaway is a former CEO of both ArmaGen and CEBIX.
Dr. Miguel de los Rios, Scientific Advisor
Miguel de los Rios, Ph.D. is trained in protein engineering and polymer biophysical chemistry, and is a Founder and the Chief Executive Officer of RIFT Biotherapeutics. He is also Vice President of Research and Development at Sevion Therapeutics, a publicly traded therapeutics company with a focus in oncology and autoimmune disorders. Previously, Miguel founded Chimeros, Inc., a venture-backed biologics therapeutic company. At Chimeros, he served as both the CEO as well as the CSO from 2003-2011, and was the inventor of the company’s core technologies. He received his Ph.D. in Biophysical Chemistry and a B.S. in Cell Biology, both at the University of California, Santa Barbara. He also advises venture capital firms and is a member of the UC Innovation Council, which advises the UC President on building a UC system-wide culture of entrepreneurial innovation. Miguel is lead author or inventor on 50 scientific publications, patents and patent applications.
Dr. Robert Eastlack, Scientific Advisor
Robert Eastlack, M.D., is the Director of spine research at Scripps Clinic and Associate Director of San Diego Spine Fellowship at San Diego Center for Spinal Disorders. Dr. Eastlack is a spinal surgeon with over 15 years of experience in surgical management of spinal cord injury patients. His experience in human spinal cord injury case management, as well as spinal cord injury clinical trials, make Dr. Eastlack an invaluable asset to the Novoron team.
Dr. Alban Gaultier, Scientific Advisor
Alban Gaultier, Ph.D., is an Assistant Professor in the Department of Neuroscience at the University of Virginia. He is an expert in MS as well as a co-inventor of Novoron’s original IP. Dr. Gaultier and Dr. Stiles have worked closely together since before Novoron’s inception to develop the technology foundation for the development of a therapeutic to enhance remyelination in MS.
Dr. Jeffrey Goldberg, Scientific Advisor
Jeffrey Goldberg, M.D., Ph.D. is professor and chair of Ophthalmology at the Byers Eye Institute at Stanford University. His research is directed at neuroprotection and regeneration of retinal ganglion cells and the optic nerve, a major unmet need in glaucoma and other optic neuropathies. Dr. Goldberg received his B.S. magna cum laude from Yale University, and his M.D. and Ph.D. from Stanford University where he made significant discoveries about the failure of optic nerve regeneration. He did his clinical training in ophthalmology and then in glaucoma at the Bascom Palmer Eye Institute and was awarded a fellowship from the Heed Foundation. He was named the 2010 Scientist of the Year by the Hope for Vision foundation and received the Cogan award from the Association for Research in Vision and Ophthalmology in 2012. In addition, he was elected in 2010 to the American Society of Clinical Investigation, an honorary society of physician scientists.
Dr. Revere Kinkel, Scientific Advisor
Revere Kinkel, M.D., is director of the multiple sclerosis (MS) program at UC San Diego Health and leads the program’s clinical, research, and educational efforts within the Department of Neurosciences. Dr. Kinkel is an internationally recognized expert in MS with extensive experience in MS clinical trials. Prior to UC San Diego, Dr. Kinkel also served as Medical Director of the Mellen Center for Multiple at Cleveland Clinic, Division Chief for the section of demyelinating diseases at Beth Israel Deaconess Medical Center in Boston, and Associate Professor of Neurology at Harvard Medical School. In 2013, Dr. Kinkel received the Walter Cove Award for Innovation from the Accelerated Cure Project for his work in MS. In addition to Novoron, Dr. Kinkel also sits on the Scientific Advisory Board of the Accelerated Cure Project for Multiple Sclerosis and is a member of the Scientific Advisory Committee for the National Multiple Sclerosis Society. He has also served on and chaired committees for the American Academy of Neurology and the Consortium of Multiple Sclerosis Centers and scientific study sections at the NMSS.